3. February 2010 23:46
Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.
[More]
b36c40c8-1a20-43fa-b6ff-ebb9a10a7d09|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antibody, Avastin, Bevacizumab, Cancer, Capecitabine, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Fluorouracil, Irinotecan, Monoclonal Antibody, Multiple Myeloma, New Drug Application, Oncology, Oxaliplatin, Perifosine, Vectibix, VEGF, Xeloda
30. January 2010 00:46
The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.
[More]
3caed714-842f-4963-90c6-308a62ec1423|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anthracycline, Antibody, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Diarrhea, Hormonal Therapy, Hormone, Nausea, Oncology, Xeloda
29. January 2010 23:25
GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.
[More]
7e6ebe27-9b6a-4665-afd9-2b34d51f113f|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Anthracycline, Aromatase Inhibitor, Breast Cancer, Cancer, Capecitabine, Cell, Cell Proliferation, Chemotherapy, Diarrhea, Hormonal Therapy, Hormone, Hypersensitivity, Nausea, Oncology, Xeloda
14. December 2009 05:24
Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.
[More]
118ca459-b9cd-45a6-9eb7-f0ecc820c1bf|1|5.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Gemcitabine, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vinorelbine, Vomiting, Wound Healing
14. December 2009 05:09
Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.
[More]
6d9124f6-536f-4b9e-9949-1ba5bfbccf5c|1|5.0
Posted in: Medical Condition News
Tags: Angiogenesis, Aromatase Inhibitor, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Estrogen, Glucose Metabolism, Hormone, Hospital, Kidney Cancer, Liver Cancer, Metabolism, Neuropathy, Obstetrics, Oncology, Oxidative Stress, Paclitaxel, Sorafenib, Stem Cell, Stress
14. December 2009 02:56
Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
[More]
56aa712b-79cf-47f2-b391-2e60e2309793|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Alopecia, Anemia, Anorexia, Breast Cancer, Cancer, Capecitabine, Cell, Cell Proliferation, Congestive Heart Failure, Diarrhea, Heart Failure, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Paclitaxel, Peripheral Neuropathy, Pfizer, Renal Failure, Vinorelbine, Vomiting
14. December 2009 02:46
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
[More]
ac2aa378-31ef-4051-a995-c2ca15cd9fbd|0|.0
Posted in: Drug Trial News
Tags: Abdominal Pain, Adjuvant Therapy, Alopecia, Anemia, Angiogenesis, Bevacizumab, Blood Pressure, Breast Cancer, Cancer, Capecitabine, Carcinoma, Cardiology, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diabetes, Diarrhea, Docetaxel, Dyspnea, Gemcitabine, Hematology, Hepatocellular Carcinoma, Kidney Cancer, Liver Cancer, Multiple Myeloma, Multiple Sclerosis, Nausea, Neutropenia, Nexavar, Oncology, Paclitaxel, Sorafenib, Weight Loss
14. December 2009 02:13
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).
[More]
1c232c6b-9503-49e3-874b-00aa29507189|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Angina, Anthracycline, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Diarrhea, Heart Failure, Nausea, Oncology, Pregnancy, Vomiting, Xeloda
14. December 2009 01:39
Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.
[More]
7f4dfcac-2dca-4d1d-8697-0aef8b2abb20|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Anthracycline, Antibody, Back Pain, Biotechnology, Brain, Breast Cancer, Cancer, Capecitabine, Chemotherapy, Monoclonal Antibody, Nausea, Thrombocytopenia
14. December 2009 00:14
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).
[More]
4. December 2009 08:58
Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.
[More]
2460e2c2-8333-4384-8e19-4a39a2d67e8a|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Abdominal Pain, Adjuvant Therapy, Angiogenesis, Anorexia, Aromatase Inhibitor, Bone, Breast Cancer, Cancer, Capecitabine, Carcinoma, Cell, Congestive Heart Failure, Constipation, Creatinine, Diarrhea, Estrogen, Heart Failure, Hormone, Hypersensitivity, Imatinib Mesylate, Kinase Inhibitor, Melanoma, Nausea, Nursing, Oncology, Paclitaxel, Pfizer, Sunitinib, Tamoxifen, Vinorelbine, Vomiting
17. November 2009 03:36
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
[More]
52d6ae04-8005-4377-aa8f-72b645331f28|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing
11. November 2009 03:43
An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.
[More]
f9a26b2b-e4b5-4bd0-9640-1af3a9b6dbc7|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Adjuvant Therapy, Breast Cancer, Cancer, Capecitabine, Chemotherapy, Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Hospital, Metastasis, Oncology, Xeloda
6. November 2009 07:38
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.
[More]
c33ab7fd-4a47-496c-ab34-49adcecd0d14|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alopecia, Anemia, Arsenic, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Gleevec, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Testicular Cancer, Xeloda
22. October 2009 08:08
Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.
[More]
fc89edfd-87d8-443c-bf50-560729ad8450|0|.0
Posted in: Business / Finance
Tags: Abilify, Angioplasty, Antibody, Apixaban, Arthritis, Cancer, Capecitabine, Cardiology, Chemotherapy, Colorectal Cancer, Diabetes, Diabetes Mellitus, Hemostasis, Hepatitis B, Immunology, Medicaid, Medicare, Metformin, Nutrition, Oncology, Onglyza, Oxaliplatin, Plavix, Prescription Drug, Rheumatoid Arthritis, Saxagliptin, Sprycel, Stroke, Thrombosis, Type 2 Diabetes
Subscribe